Hofer & Associates’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.42M Sell
3,668
-108
-3% -$40.1K 0.69% 29
2026
Q1
$1.11M Buy
3,776
+40
+1% +$13.1K 0.59% 31
2025
Q4
$1.31M Buy
3,736
+2
+0.1% +$676 0.69% 29
2025
Q3
$1.21M Sell
3,734
-225
-6% -$70K 0.69% 30
2025
Q2
$1.54M Sell
3,959
-369
-9% -$148K 0.96% 26
2025
Q1
$1.88M Buy
4,328
+83
+2% +$33.3K 1.28% 24
2024
Q4
$1.57M Hold
4,245
1.05% 25
2024
Q3
$2.21M Sell
4,245
-84
-2% -$44.9K 1.52% 21
2024
Q2
$2.35M Buy
4,329
+3
+0.1% +$1.59K 1.82% 20
2024
Q1
$2.24M Sell
4,326
-59
-1% -$29.3K 1.89% 19
2023
Q4
$2.07M Buy
4,385
+146
+3% +$67.5K 1.92% 17
2023
Q3
$1.85M Buy
4,239
+69
+2% +$31.3K 1.89% 17
2023
Q2
$1.85M Buy
4,170
+267
+7% +$123K 1.78% 18
2023
Q1
$2M Hold
3,903
2% 16
2022
Q4
$2M Sell
3,903
-15
-0.4% -$7.62K 2% 17
2022
Q3
$1.78M Hold
3,918
1.91% 18
2022
Q2
$1.89M Hold
3,918
1.97% 18
2022
Q1
$1.93M Buy
3,918
+1,804
+85% +$825K 1.69% 18
2021
Q4
$980K Buy
+2,114
New +$889K 0.89% 21

Other funds holding ELV

Hofer & Associates's ELV Position: Q2 2026 in Review

Hofer & Associates reduced its Elevance Health (ELV) stake by 2.9% in Q2 2026, selling an estimated $40.1K and leaving 3,668 shares worth $1.42M. The position accounts for 0.69% of the portfolio, ranked #29.

Hofer & Associates first reported a position in ELV in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.35M in Q2 2024. 417 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Hofer & Associates held 3,668 shares of Elevance Health worth $1.42M as of Q2 2026.
  • Hofer & Associates sold 108 Elevance Health shares in Q2 2026, an estimated $40.1K.
  • Elevance Health made up 0.69% of Hofer & Associates's portfolio in Q2 2026, its #29 holding.
  • Hofer & Associates first reported a position in Elevance Health in Q4 2021 and has held it in 19 quarters since.
  • Hofer & Associates's Elevance Health position peaked at $2.35M in Q2 2024.
  • 417 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Hofer & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.